Program
PRMT5 Inhibitor AZD3470
Its studies are mostly in Lymphoma, led by AstraZeneca.
Furthest: phase 2, since Oct 19, 20232 company-led studies, 2 open or runningNext primary completion: Dec 4, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 22 open or running | phase 2since Oct 19, 2023 | Oct 19, 2023 | Dec 4, 2028phase 2 · NCT06130553 |
- Named in AstraZeneca’s own pipeline as
AZD3470
, phase 2, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2023First study: phase 2 study in Advanced Solid Tumors That Are MTAP DeficientFirst studyNCT06130553 · 334 planned · United States, Australia, China and more
- Nov 2, 2023Phase 2 study in LymphomaNCT06137144 · 161 planned · United States, Australia, Brazil and more
Ahead
- Dec 4, 2028Primary completion: phase 2 study in Advanced Solid Tumors That Are MTAP DeficientNCT06130553
- May 3, 2029Primary completion: phase 2 study in LymphomaNCT06137144
TargetBeta
“An orally bioavailable second generation methylthioadenosine (MTA)-selective small molecule inhibitor of the protein arginine methyltransferase 5 (PRMT5), with potential antineoplastic activity. Upon oral administration, PRMT5 inhibitor AZD3470 inhibits PRMT5 in the presence of MTA, thereby speci…”NCIt, read by Claude
Other programs on PRMT5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| navlimetostat | Bristol-Myers Squibb | phase 3 | 10 |
| JBI-778rule | jubilant-therapeutics-india-limited | phase 2 | 2 |
| PRMT5 Inhibitor TNG456rule | tango-therapeutics-inc | phase 2 | 1 |
| PRMT5 Inhibitor BAY 3713372rule | Bayer | phase 2 | 1 |
| onametostatrule | Johnson & Johnson | phase 1 | 2 |
| PRMT5 Inhibitor SH3765rule | Nanjing Sanhome Pharmaceutical | phase 1 | 2 |
| PRMT5 Inhibitor BGB-58067rule | BeOne Medicines | phase 1 | 2 |
| PRMT5 Inhibitor IDE892rule | ideaya-biosciences | phase 1 | 1 |
| PEP08rule | pharmaengine | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06137144Lymphoma · United States, Australia, Brazil and more | 2 | Recruiting | May 3, 2029 | 161 |
| NCT06130553Advanced Solid Tumors That Are MTAP Deficient · United States, Australia, China and more | 2 | Recruiting | Dec 4, 2028 | 334 |
How it is read
Names in the registry
- “AZD3470”, 2 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.